John Orwin is listed as an executive officer and director on 7 SEC Form D filings by 3 issuers between Aug 2011 and Mar 2023: Atreca, Inc. (Redwood City, CA — biotechnology — 2018; $125M reported sold to 88 investors), CARGO Therapeutics, Inc. (San Mateo, CA — biotechnology — 2023; $68.8M reported sold to 19 investors) and NeurogesX Inc (San Mateo, CA — pharmaceuticals — 2011–2012; $20.2M reported sold to 29 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as executive officer and director, over about 12 years. Across those companies the filings report $214M sold in total.
Listed alongside Anthony DiTonno (5 shared filings), Bradford Goodwin (5 shared filings), Gary Lyons (5 shared filings), Neil Kurtz (5 shared filings), Robert Nelsen (5 shared filings) and 22 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around John. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 3 court cases matching the name, 2 bankruptcy cases matching the name listed in Key records below.
What this means 5 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 7 public filings for John Orwin and found 5 differences: Form D filed 20 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.